GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PetIQ Inc (NAS:PETQ) » Definitions » Beneish M-Score

PetIQ (PETQ) Beneish M-Score : -2.53 (As of May. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is PetIQ Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.53 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for PetIQ's Beneish M-Score or its related term are showing as below:

PETQ' s Beneish M-Score Range Over the Past 10 Years
Min: -3.37   Med: -2.54   Max: 0.23
Current: -2.53

During the past 9 years, the highest Beneish M-Score of PetIQ was 0.23. The lowest was -3.37. And the median was -2.54.


PetIQ Beneish M-Score Historical Data

The historical data trend for PetIQ's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetIQ Beneish M-Score Chart

PetIQ Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only -2.17 -2.85 -2.72 -2.89 -2.55

PetIQ Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.68 -3.07 -2.85 -2.55 -2.53

Competitive Comparison of PetIQ's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, PetIQ's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PetIQ's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PetIQ's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where PetIQ's Beneish M-Score falls into.



PetIQ Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of PetIQ for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7889+0.528 * 0.9672+0.404 * 0.9257+0.892 * 1.1961+0.115 * 0.7525
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9559+4.679 * 0.007726-0.327 * 0.9821
=-2.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $192 Mil.
Revenue was 308.443 + 219.926 + 277.019 + 314.547 = $1,120 Mil.
Gross Profit was 74.543 + 43.99 + 72.611 + 73.879 = $265 Mil.
Total Current Assets was $445 Mil.
Total Assets was $875 Mil.
Property, Plant and Equipment(Net PPE) was $73 Mil.
Depreciation, Depletion and Amortization(DDA) was $44 Mil.
Selling, General, & Admin. Expense(SGA) was $203 Mil.
Total Current Liabilities was $184 Mil.
Long-Term Debt & Capital Lease Obligation was $450 Mil.
Net Income was 14.907 + -17.487 + 0.451 + 9.468 = $7 Mil.
Non Operating Income was 0.126 + -11.198 + -8.27 + -0.151 = $-19 Mil.
Cash Flow from Operations was -85.144 + -2.842 + 50.326 + 57.73 = $20 Mil.
Total Receivables was $203 Mil.
Revenue was 290.471 + 184.079 + 209.725 + 252.014 = $936 Mil.
Gross Profit was 62.261 + 39.284 + 50.77 + 61.974 = $214 Mil.
Total Current Assets was $397 Mil.
Total Assets was $868 Mil.
Property, Plant and Equipment(Net PPE) was $88 Mil.
Depreciation, Depletion and Amortization(DDA) was $35 Mil.
Selling, General, & Admin. Expense(SGA) was $178 Mil.
Total Current Liabilities was $186 Mil.
Long-Term Debt & Capital Lease Obligation was $454 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(191.862 / 1119.935) / (203.325 / 936.289)
=0.171315 / 0.217161
=0.7889

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(214.289 / 936.289) / (265.023 / 1119.935)
=0.228871 / 0.236641
=0.9672

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (444.915 + 73.4) / 875.236) / (1 - (397.152 + 88.318) / 867.715)
=0.4078 / 0.440519
=0.9257

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1119.935 / 936.289
=1.1961

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(34.965 / (34.965 + 88.318)) / (44.399 / (44.399 + 73.4))
=0.283616 / 0.376905
=0.7525

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(203.118 / 1119.935) / (177.651 / 936.289)
=0.181366 / 0.189739
=0.9559

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((449.788 + 183.998) / 875.236) / ((453.597 + 186.187) / 867.715)
=0.724132 / 0.73732
=0.9821

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(7.339 - -19.493 - 20.07) / 875.236
=0.007726

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

PetIQ has a M-score of -2.53 suggests that the company is unlikely to be a manipulator.


PetIQ (PETQ) Business Description

Traded in Other Exchanges
Address
230 East Riverside Drive, Eagle, ID, USA, 83616
PetIQ Inc is a manufacturer and distributor of health and wellness products for dogs and cats. The company offers veterinarian-grade pet Rx medications, OTC flea and tick preventatives, vitamins treats, nutritional supplements, and hygiene products. The group operates in two segments namely the Products and Services segments. It also provides third-party products to retailers which for a long time were primarily available from veterinary clinics only. Its proprietary brands include PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, TruProfen, Betsy Farms, PetAction, Minties, Vera and Delightibles. The company generates maximum revenue from Products segment.
Executives
William J. Carter officer: EVP, GENERAL COUNSEL C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
John Paul Pearson officer: EVP, Services & Manufactured C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Robert Michael Herrman officer: General Counsel and Secretary 923 SOUTH BRIDGEWAY PLACE, EAGLE ID 83616
Michael A Smith officer: EVP - Products 923 S. BRIDGEWAY PLACE, C/O PETIQ, INC., EAGLE ID 83616
Kimberly Lefko director 923 S. BRIDGEWAY PLACE, EAGLE ID 83616
Sheryl Oloughlin director 923 S. BRIDGEWAY PLACE, EAGLE ID 83616
Scott Huff director 923. S. BRIDGEWAY PLACE, EAGLE ID 83616
Allan Hall director C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Zvi Glasman officer: Chief Financial Officer C/O FOX FACTORY HOLDING CORP., 915 DISC DRIVE, SCOTTS VALLEY CA 95066
Kenneth C. Walker director C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Susan Sholtis director C/O PETIQ, INC., 500 E. SHORE DRIVE, SUITE 120, EAGLE ID 83616
Mccord Christensen director, officer: Chief Executive Officer 500 EAST SHORE DRIVE, SUITE 120, EAGLE ID 83616
John Newland officer: Chief Financial Officer C/O TRUE SCIENCE LLC, 500 E. SHORE DRIVE SUITE 120, EAGLE ID 83616
Ronald Kennedy director, 10 percent owner 500 EAST SHORE DR, SUITE 120, EAGLE ID 83616
Ecp Helios Partners Iv, L.p. 10 percent owner 437 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022